Neutral · 60/100Sep 23, 8:57 PM EDT
FDA Advisory Panel Backs GRAIL's Galleri Multi-Cancer Blood Test
GRAL
An FDA advisory committee voted 6-4 that there is reasonable evidence supporting the effectiveness of GRAIL's Galleri multi-cancer early detection blood test. The endorsement could pave the way for regulatory approval, a key catalyst for GRAIL (GRAL). For inve…
- ▹FDA panel endorsement (6-4) supports regulatory path for Galleri, but narrow margin and no approval yet
- ▹Multi-cancer early detection platform has differentiation, but commercial adoption and reimbursement remain uncertain